KEY MEMBERS

NeoImmuneTech, Inc. (NIT) is led by seasoned executives relentlessly pursuing the development of novel drug in immuno-oncology.

Luke Oh Ph.D. - President and Chief Executive Officer
Dr. Luke Oh has a Ph.D. in Neuroimmunology from the McGill University(Montreal, Canada), and he has held various roles in research and development for leading organizations such as Mallinckrodt Pharmaceuticals, Human Genome Sciences, and Vertex Pharmaceuticals. Also Dr. Oh is an expert in regulatory experience at the U.S. FDA. He has over 20 years of experience, including experience overseeing clinical operations as Samsung Bioepis.

KEY MEMBERS

Clinical Division
Byung Ha Lee
Ph.D.

Chief Scientific Officer
/ Head of Clinical Division

Hye Jeong
M.D.

Medical Director of Drug
Safety and Pharmacovigilance

Sara Ferrando Martinez
Ph.D.

Head of Clinical Sciences

Advisor
Jiyoung Joo

Advisor

Quality Assurance Division
Hee Yong Jeong

Director
of CMC QA

Richard Sloma

Senior Director of
Clinical QA

CMC Division
Eun Jeong Bae

Head of CMC Division

Regulatory Affairs Division
Alicia Staz

RA Director

Research Institute
Donghoon Choi
Ph.D.

Chief Technology Officer
/ Head of Research Institute

Business Development
Daniel Rho

Director of Business
Development

Global Strategy Department
Hyun Jee Kim

Head of Global
Strategy Department

Finance Division
Tae Woo Kim
CPA

Chief Financial Officer
/ Head of Finance Division

Management Division
Gene Namgoong

Chief Operating Officer
/ Head of Management Division

Dana Wyche

IT Director

Soon Phil Lee

Head of Management Department (KR)